"Killer Cells, Natural" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
| Descriptor ID |
D007694
|
| MeSH Number(s) |
A11.118.637.555.567.537 A15.145.229.637.555.567.537 A15.382.490.555.567.537
|
| Concept/Terms |
Killer Cells, Natural- Killer Cells, Natural
- NK Cells
- Cell, NK
- Cells, NK
- NK Cell
- Natural Killer Cells
- Cell, Natural Killer
- Cells, Natural Killer
- Killer Cell, Natural
- Natural Killer Cell
|
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Natural".
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Natural".
This graph shows the total number of publications written about "Killer Cells, Natural" by people in this website by year, and whether "Killer Cells, Natural" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 5 | 0 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 4 | 0 | 4 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Killer Cells, Natural" by people in Profiles.
-
Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Cancer Lett. 2025 Jan 01; 608:217319.
-
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3?/ZAP70 Signaling Axis. Cancer Discov. 2024 Oct 04; 14(10):1879-1900.
-
Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2024; 15:1442673.
-
Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice. Front Immunol. 2023; 14:1067369.
-
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022 Oct; 28(10):2133-2144.
-
IL-2 and Zoledronic Acid Therapy Restores the In Vivo Anti-Leukemic Activity of Human Lymphocytes Pre-Exposed to Simulated Microgravity. Front Biosci (Landmark Ed). 2022 07 08; 27(7):215.
-
Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production. Cell Immunol. 2022 Jan; 371:104457.
-
FceRI?-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv. 2021 Aug 10; 5(15):3021-3031.
-
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.
-
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. Blood Adv. 2020 04 14; 4(7):1388-1406.